Skip to content

Clinical trials

Observational Atrial Fibrillation trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Atrial Fibrillation Phase: Observational Country / region: United States Clear all

293 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20021
20031
20042
20059
20064
20075
200810
200910
201012
20116
201211
20139
201416
20157
201619
201714
201817
201916
202022
202119
202221
202313
202424
20258
202612

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed162
Recruiting39
Terminated29
Unknown status23
Active, not recruiting19
Withdrawn10
Enrolling by invitation7
Not yet recruiting4

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
The Cleveland Clinic13
Brigham and Women's Hospital11
Abbott Medical Devices9
Boehringer Ingelheim9
Bayer8
Heart Rhythm Clinical and Research Solutions, LLC8
Kansas City Heart Rhythm Research Foundation7
Texas Cardiac Arrhythmia Research Foundation7
Boston Scientific Corporation6
Emory University6

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Atrial Fibrillation293
Arrhythmias, Cardiac47
Stroke26
Heart Failure20
Atrial Flutter19
Tachycardia, Ventricular10
Tachycardia9
Cardiovascular Diseases7
Heart Diseases7
Hemorrhage7

Trials

Showing 1 to 25 of 293. Each trial links to its page on Pharma Observatory.

193 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.